Featured conditions Brain tumor, breast cancer, colon cancer, congenital heart disease, heart arrhythmia. See more conditions.
Featured conditions
(for at least one location)
Rochester, MN
Describes the nature of a clinical study. Types include:
Study Objectives:
1. To assess the efficacy of Daratumumab therapy in cardiac transplant recipients with resistant antibody mediated rejection
2. To evaluate the efficacy of Daratumumab as an HLA desensitization strategy prior to cardiac transplantation in highly sensitized patients
Study statuses change often. Please contact us for help.
Contact us for the latest status
The purpose of this study is to examine the effects of a health coaching intervention on the stress and burden of caregivers of patients awaiting heart or lung transplant.
Hypotheses: Caregivers will have traits and behaviors pre-transplant that will predict caregiver readiness, quality of life, and transplant recipient outcomes. Specifically, thoracic pre-transplant caregivers report stress, symptoms of anxiety or depression, and perceive high caregiver burden. These factors may be amenable to pre-transplant intervention to improve overall patient and caregiver outcomes.
Aims, purpose, or objectives: We will conduct a pilot trial to test whether caregivers of heart and lung transplant candidates who receive wellness coaching will experience improvement in caregiver-related distress. We will also explore the relationship between caregiving and factors such as uncertainty, resilience, stress level, and affect.
Open for enrollment
This study is being done to develop a serum and tissue bank for future research of patients with heart failure, mechanical circulatory support and/or cardiothoracic transplants. This blood/tissue will be used for three principle purposes: (1) laboratory tests which will be available in the future but that are not currently available and which may be of benefit to the patient, (2) review of previous patient laboratory results made necessary by development of a new disease process by the patient, and (3) future unspecified research purposes.
Currently transplant caregivers are viewed as healthy volunteers caring for patients following heart or lung transplant. However research has revealed that thoracic transplant caregivers have increased mood disorders, distress, and high caregiver burden, especially while caring for patients on the organ transplant waiting list. By monitoring caregiver traits and behaviors we will be better able to provide care and services for CG to improve both CG and patient outcomes.
Jacksonville, FL, Rochester, MN
The purpose of this study is to determine if DNA originating from the transplanted heart or lung can be detected in the blood and used to monitor for rejection.
Jacksonville, FL
The puprose of this study is to evaluate pharmacogenomic differences of CYP 3A5 in heart transplant patients, to determine dose ranges and pharmacodynamics properties of tacrolimus metabolism based on CYP 3A5 genotype/phenotype combinations, and to assess whether CYP3A5 polymorphism influences post-transplant outcomes including survival, rejection and infection rates.
The purpose of this study is to collect surgically removed atrial tissue for genetic, pathologic, metabolic, and molecular studies in patients with or without a history of atrial fibrillation.
The purpose of this retrospective and prospective study is to evaluate tissue bank from donors and recipients who underwent heart and lung transplant in order to study the Role of Mitochondrial DNA in Encoding Histocompatibility Antigens in humans and rejection.
The purpose of this study is to obtain electro-anatomic maps of human myocardium in sinus rhythm and ventricular arrhythmias to identify activation patterns, identify and perform tissue ablation at targeted sites of interest that could play an important trigger for development of arrhythmias, and to perform histologic analysis of the myocardial tissue to identify triggers and/or targets for therapies to terminate ventricular arrhythmias.
The purpose of this study is to determine the safety of the SARS-CoV-2 vaccination in patients listed for solid organ transplantation, including heart, lung, liver, kidney, and pancreas.